Triple Combination Therapy and Drug Cycling—Tangential Strategies for Countering Artemisinin Resistance

Bhattacharjee Dipanjan, G. Shivaprakash, O. Balaji

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of Review: This review attempts to understand the reasons for the successes and failures of the two novel strategies that have slowly begun to emerge as potential counters for anti-malarial drug resistance—“Triple Combination Therapy” and “Drug Cycling.” Recent Findings: Recent reports have suggested that increasing the heterogeneity within the parasite’s environment, both at an individual and the population level, may help raise the probabilistic barrier of development of resistance in the parasite. The encouraging results following the implementation of a few experimental triple combination therapies like atovaquone–proguanil–artesunate along with the re-emergence of chloroquine sensitive Plasmodium falciparum parasites in the sub-Saharan African nations have re-kindled mankind’s hope of curbing anti-malarial drug resistance. Summary: The addition of a third drug with traits like a medium half-life and benign safety profile is crucial to achieving SERCAP (single encounter radical cure and preventive therapy), the principle of a triple combination therapy. Simultaneously, the plausible reasons behind the re-emergence of chloroquine sensitive Plasmodium falciparum malaria in the high transmission regions could be the re-expansion of an existing chloroquine susceptible parasite reservoir and a greater predisposition towards the development of polyclonal infections. Another potential reason for this observation could be an impaired deoxyribonucleic acid (DNA) repair mechanisms in the south-east Asian Plasmodium falciparum parasites. These strategies may potentially emerge as the key players in warding off anti-malarial drug resistance in the near future. However, their implementation would be dictated by a host of factors like the epidemiological knowledge, population pharmacokinetics, drug-resistance patterns, cost, availability, and ease of adherence.

Original languageEnglish
Article number25
JournalCurrent Infectious Disease Reports
Volume19
Issue number7
DOIs
Publication statusPublished - 01-07-2017

Fingerprint

Combination Drug Therapy
Parasites
Chloroquine
Antimalarials
Drug Resistance
Plasmodium falciparum
Falciparum Malaria
Drug Combinations
Population
Half-Life
Therapeutics
Pharmacokinetics
artemisinine
Safety
Costs and Cost Analysis
DNA
Infection
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

@article{a74ce72bb96c4fec9d1a08aba702e6d3,
title = "Triple Combination Therapy and Drug Cycling—Tangential Strategies for Countering Artemisinin Resistance",
abstract = "Purpose of Review: This review attempts to understand the reasons for the successes and failures of the two novel strategies that have slowly begun to emerge as potential counters for anti-malarial drug resistance—“Triple Combination Therapy” and “Drug Cycling.” Recent Findings: Recent reports have suggested that increasing the heterogeneity within the parasite’s environment, both at an individual and the population level, may help raise the probabilistic barrier of development of resistance in the parasite. The encouraging results following the implementation of a few experimental triple combination therapies like atovaquone–proguanil–artesunate along with the re-emergence of chloroquine sensitive Plasmodium falciparum parasites in the sub-Saharan African nations have re-kindled mankind’s hope of curbing anti-malarial drug resistance. Summary: The addition of a third drug with traits like a medium half-life and benign safety profile is crucial to achieving SERCAP (single encounter radical cure and preventive therapy), the principle of a triple combination therapy. Simultaneously, the plausible reasons behind the re-emergence of chloroquine sensitive Plasmodium falciparum malaria in the high transmission regions could be the re-expansion of an existing chloroquine susceptible parasite reservoir and a greater predisposition towards the development of polyclonal infections. Another potential reason for this observation could be an impaired deoxyribonucleic acid (DNA) repair mechanisms in the south-east Asian Plasmodium falciparum parasites. These strategies may potentially emerge as the key players in warding off anti-malarial drug resistance in the near future. However, their implementation would be dictated by a host of factors like the epidemiological knowledge, population pharmacokinetics, drug-resistance patterns, cost, availability, and ease of adherence.",
author = "Bhattacharjee Dipanjan and G. Shivaprakash and O. Balaji",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s11908-017-0579-4",
language = "English",
volume = "19",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "7",

}

Triple Combination Therapy and Drug Cycling—Tangential Strategies for Countering Artemisinin Resistance. / Dipanjan, Bhattacharjee; Shivaprakash, G.; Balaji, O.

In: Current Infectious Disease Reports, Vol. 19, No. 7, 25, 01.07.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Triple Combination Therapy and Drug Cycling—Tangential Strategies for Countering Artemisinin Resistance

AU - Dipanjan, Bhattacharjee

AU - Shivaprakash, G.

AU - Balaji, O.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose of Review: This review attempts to understand the reasons for the successes and failures of the two novel strategies that have slowly begun to emerge as potential counters for anti-malarial drug resistance—“Triple Combination Therapy” and “Drug Cycling.” Recent Findings: Recent reports have suggested that increasing the heterogeneity within the parasite’s environment, both at an individual and the population level, may help raise the probabilistic barrier of development of resistance in the parasite. The encouraging results following the implementation of a few experimental triple combination therapies like atovaquone–proguanil–artesunate along with the re-emergence of chloroquine sensitive Plasmodium falciparum parasites in the sub-Saharan African nations have re-kindled mankind’s hope of curbing anti-malarial drug resistance. Summary: The addition of a third drug with traits like a medium half-life and benign safety profile is crucial to achieving SERCAP (single encounter radical cure and preventive therapy), the principle of a triple combination therapy. Simultaneously, the plausible reasons behind the re-emergence of chloroquine sensitive Plasmodium falciparum malaria in the high transmission regions could be the re-expansion of an existing chloroquine susceptible parasite reservoir and a greater predisposition towards the development of polyclonal infections. Another potential reason for this observation could be an impaired deoxyribonucleic acid (DNA) repair mechanisms in the south-east Asian Plasmodium falciparum parasites. These strategies may potentially emerge as the key players in warding off anti-malarial drug resistance in the near future. However, their implementation would be dictated by a host of factors like the epidemiological knowledge, population pharmacokinetics, drug-resistance patterns, cost, availability, and ease of adherence.

AB - Purpose of Review: This review attempts to understand the reasons for the successes and failures of the two novel strategies that have slowly begun to emerge as potential counters for anti-malarial drug resistance—“Triple Combination Therapy” and “Drug Cycling.” Recent Findings: Recent reports have suggested that increasing the heterogeneity within the parasite’s environment, both at an individual and the population level, may help raise the probabilistic barrier of development of resistance in the parasite. The encouraging results following the implementation of a few experimental triple combination therapies like atovaquone–proguanil–artesunate along with the re-emergence of chloroquine sensitive Plasmodium falciparum parasites in the sub-Saharan African nations have re-kindled mankind’s hope of curbing anti-malarial drug resistance. Summary: The addition of a third drug with traits like a medium half-life and benign safety profile is crucial to achieving SERCAP (single encounter radical cure and preventive therapy), the principle of a triple combination therapy. Simultaneously, the plausible reasons behind the re-emergence of chloroquine sensitive Plasmodium falciparum malaria in the high transmission regions could be the re-expansion of an existing chloroquine susceptible parasite reservoir and a greater predisposition towards the development of polyclonal infections. Another potential reason for this observation could be an impaired deoxyribonucleic acid (DNA) repair mechanisms in the south-east Asian Plasmodium falciparum parasites. These strategies may potentially emerge as the key players in warding off anti-malarial drug resistance in the near future. However, their implementation would be dictated by a host of factors like the epidemiological knowledge, population pharmacokinetics, drug-resistance patterns, cost, availability, and ease of adherence.

UR - http://www.scopus.com/inward/record.url?scp=85020902596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020902596&partnerID=8YFLogxK

U2 - 10.1007/s11908-017-0579-4

DO - 10.1007/s11908-017-0579-4

M3 - Review article

AN - SCOPUS:85020902596

VL - 19

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 7

M1 - 25

ER -